# 1 Title: Enhanced differentiation of IgA\* class-switched CD27<sup>-</sup>CD21<sup>+</sup> B cells in 2 patients with IgA nephropathy

3

# 4 Authors:

Anna Popova<sup>1,2,3†</sup>, Baiba Slisere<sup>4,5†</sup>, Karlis Racenis<sup>1,2,6†</sup>, Viktorija Kuzema<sup>1,6†</sup>, Roberts
Karklins<sup>6</sup>, Mikus Saulite<sup>1,6</sup>, Janis Seilis<sup>1</sup>, Anna Jana Saulite<sup>1</sup>, Aiga Vasilvolfa<sup>1,3,6</sup>,
Kristine Vaivode<sup>7</sup>, Dace Pjanova<sup>7</sup>, Juta Kroica<sup>2</sup>, Harijs Cernevskis<sup>1,6</sup>, Aivars
Lejnieks<sup>6,8</sup>, Aivars Petersons<sup>1,6</sup>, Kristine Oleinika<sup>6,9\*</sup>

9

# 10 Affiliations:

- 11 1 Department of Nephrology, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 12 2 Department of Biology and Microbiology, Riga Stradins University, Riga, Latvia
- 13 3 Department of Internal Medicine, University of Latvia, Riga, Latvia
- 14 4 Joint Laboratory, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 15 5 Department of Doctoral Studies, Riga Stradins University, Riga, Latvia
- 16 6 Department of Internal Diseases, Riga Stradins University, Riga, Latvia
- 17 7 Institute of Microbiology and Virology, Riga Stradins University, Riga, Latvia
- 18 8 Riga East Clinical University Hospital, Riga, Latvia
- 9 Program in Cellular and Molecular Medicine, Boston Children's Hospital, HarvardMedical
- 21 School, Boston, MA, USA
- 22 † These authors contributed equally
- 23 Correspondence to: Kristine.Oleinika@rsu.lv
- 24
- 25 **Word count** (maximum 3500): 3500
- Number of figures, tables, boxes, references: 5 figures, 1 table, 47 references.
- 27 Running head: Mechanisms of IgA<sup>+</sup> B cell differentiation in IgAN

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## 1 Abstract

Background: IgA nephropathy (IgAN) is characterised by the production of galactosedeficient IgA1 (Gd-IgA1) antibodies. As the source of pathogenic antibodies, B cells
are central to IgAN pathogenesis, but the B cell activation pathways as well as the
potential B cell source of dysregulated IgA-secretion remain unknown.

Methods: We carried out flow cytometry analysis of peripheral blood B cells in patients
with IgA nephropathy and control subjects with a focus on IgA-expressing B cells to
uncover the pathways of B cell activation in IgAN and how these could give rise to
pathogenic GdIgA1 antibodies.

Results: In addition to global changes in the B cell landscape – expansion of naive and 10 reduction in memory B cells - IgAN patients present with an increased frequency of 11 IgA-expressing B cells that lack the classical memory marker CD27, but are CD21<sup>pos</sup>. 12 IqAN patients further have an expanded population of IgA<sup>pos</sup> antibody-secreting cells, 13 which correlate with serum IgA levels. Both IgA<sup>pos</sup> plasmabalsts and CD27<sup>neg</sup> B cells 14 co-express GdlgA1. Implicating dysregulation at mucosal surfaces as the driver of 15 such B cell differentiation, we found a correlation between lipopolysaccharide (LPS) in 16 the serum and IgA<sup>pos</sup>CD27<sup>neg</sup> B cell frequency. 17

Conclusion: We propose that dysregulated immunity in the mucosa may drive-de novo B cell activation within germinal centres, giving rise to IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and subsequently IgA-producing plasmablasts. These data integrate B cells into the paradigm of IgAN pathogenesis and allow to further investigate this pathway to uncover biomarkers and develop therapeutic interventions.

## 1 Key learning points

# 2 What was known:

- Patients with IgA nephropathy (IgAN) have aberrant production of galactose deficient IgA1 (Gd-IgA1) and antibodies against it, which together form immune
   complexes that are deposited in the renal mesangium and lead to kidney
   damage; this is known as the multi-hit model of IgAN pathogenesis.
- The multi-hit model centrally implicates B cells as they produce both Gd-IgA1
   and antibodies against it, yet B cell activation pathways that lead to aberrant
   antibody production are absent from the model.
- Only isolated reports exist describing specific features of B cells that are altered
   in patients with IgAN, including a reduction in regulatory B cells, increase in toll like receptor 7 expression in total peripheral blood B cells and elevated
   frequency of circulating CCR9<sup>+</sup>IgA<sup>+</sup> B cells.

# 14 This study adds:

- In addition to changes in the overall circulating B cell landscape, differentiation
   of IgA<sup>+</sup> plasmablasts is enhanced in patients with IgAN and their levels correlate
   with serum IgA.
- IgA-expressing plasmablast frequency correlates with that of IgA<sup>+</sup>CD21<sup>+</sup> B cells,
   that lack-the classical memory B cell marker CD27.
- Both IgA<sup>+</sup> plasmablasts and IgA-expressing CD27<sup>-</sup> B cells co-express GdIgA1
   receptors.
- IgA<sup>+</sup>CD27<sup>-</sup>CD21<sup>+</sup> B cell frequency correlates with serum lipopolysaccharide
   (LPS) levels, implicating mucosa in their activation.

# 24 **Potential impact:**

- We uncover the previously unknown B cell activation pathway that appears to be associated with pathogenic IgA secretion in IgAN and integrate this into the
- 27 multi-hit model of IgAN pathogenesis.
- This pathway holds potential for further investigation to identify biomarkers and
   therapeutic targets in IgAN.

30

Keywords: B cells, IgA nephropathy, IgA-producing plasmablasts, antibodies, disease
 mechanisms

#### 1 Introduction

IaA nephropathy (IgAN) is an autoimmune disease and the most common form of 2 primary glomerulonephritis with an estimated global incidence of at least 2.5 cases per 3 100'000 adults annually (1). Patients present with heterogeneous clinicopathological 4 5 manifestations and variable prognosis, from asymptomatic changes in urinalysis to rapidly progressive glomerulonephritis (2). Up to 39% of patients progress to end-stage 6 renal disease (ESRD) over 20 years of follow-up (3). Present treatments carry severe 7 side-effects and largely fail to halt the progression of renal decline (4). The mainstay 8 of therapy is optimized supportive care, i.e., measures that lower blood pressure, 9 reduce proteinuria, minimize lifestyle risk factors, and otherwise help to reduce non-10 specific insults to the kidneys. The use of immunosuppression has become 11 controversial because of its low effectiveness and high rate of serious side effects 12 mainly associated with glucocorticoid treatment (5). However new treatment regimens 13 with low dose steroids and enteral targeted-release budesonide for high-risk patients 14 15 may decrease the rate of IgAN progression (6). Treatment advances in IgAN have been limited at least in part due to the incomplete understanding of disease 16 aetiopathogenesis. 17

The multi-hit model of IgAN aetiopathogenesis proposes that IgAN is initiated with the 18 overproduction of galactose-deficient IgA1 (Gd-IgA1), followed by the development of 19 antibodies against plgA1 (7-10). Together these form immune complexes that lead to 20 nephrotoxicity through complement activation via alternative and lectin pathways. B 21 cells are centrally implicated in the pathogenesis of IgAN as the source of 22 hypoglycosylated IgA1 and autoantibodies against it (11, 12). Nevertheless, there are 23 crucial gaps in the knowledge on B cell activation and differentiation pathways that 24 lead to secretion of pathogenic IgA antibodies in IgAN. This is particularly striking when 25 compared to the comprehensive understanding gained in other immune-mediated 26 kidney diseases, particularly systemic lupus erythematosus (13-15). 27

Isolated reports have characterised distinct aspects of B cell activation in patients with IgAN. Among the reported B cell alterations have been the reduction in regulatory B cells (16), elevated toll-like receptor 7 (TLR7) expression in circulating B cells (17) and increased frequency of CCR9<sup>pos</sup>IgA<sup>pos</sup> B cells in blood (18). However, B cell activation pathways have not been investigated and remain to be integrated into the paradigm of IgAN aetiopathogenesis. Here we carry out peripheral B cell profiling in a biopsy-

confirmed cohort of IgAN patients and healthy controls (HC) to uncover B cell activation
pathways that operate in IgAN as well as to determine the cellular pathways implicated
in the secretion of pathogenic IgA.

#### 4 Materials and Methods

Study participants. Adults with biopsy-confirmed IgAN were recruited at the 5 Nephrology Centre at Pauls Stradins Clinical University Hospital, Riga, Latvia between 6 January 2020 and June 2022. This is the only centre for kidney diseases in Latvia, 7 where IqAN is diagnosed in adults, therefore the IqAN patient cohort is representative 8 of all Latvian adults with IgAN. Age- and sex-matched healthy volunteers were also 9 enrolled. Healthy controls had age-appropriate kidney function, without active urine 10 sediment and proteinuria. Individuals with diabetes mellitus, current pregnancy, severe 11 organ dysfunction, acute cardiovascular disease, hepatic diseases, acute or chronic 12 inflammatory, autoimmune or infectious diseases, immunodeficiency, malignancies, 13 substance and alcohol abuse, kidney replacement therapy (including kidney 14 transplantation) were excluded from the study. All participants provided written 15 16 informed consent. This study was approved by the Clinical Research Ethics Committee of Pauls Stradins Clinical University Hospital (No 191219-6L) and was performed 17 18 under the guidance of the Declaration of Helsinki.

19 Clinical and laboratory characterisation. Serum creatinine, albumin and total cholesterol were measured on Atellica CH (Siemens Healthineers, Erlangen, 20 Germany). Estimated glomerular filtration rate (eGFR) was calculated using the CKD-21 EPI Creatinine Equation (2021). Serum IgA was measured on Atellica NEPH 630 22 (Siemens Healthineers, Erlangen, Germany). Proteinuria was determined by spot 23 protein-to-creatinine ratio. Assessment of protein in urine was performed on Cobas 24 Integra 400 Plus (Roche Diagnostics GmbH, Mannheim, Germany). Red blood cell 25 count in urine was determined on Atellica 1500 automated urinalysis system (Siemens 26 Healthineers, Erlangen, Germany). The complete blood counts were performed on 27 ethylenediaminetetraacetic acid (EDTA)-treated peripheral blood samples using 28 UniCel DxH cellular analysis system (Beckman Coulter, Miami, FL, USA). Serum 29 lipopolysaccharide (LPS) levels were detected by ELISA (MyBioSource MBS702450, 30 San Diego, CA, USA) according to the manufacturer's instructions. Gd-IgA1 levels in 31 serum were measured using an ELISA kit (Gd-IgA1 Assay Kit-IBL 30111694, IBL 32 33 international GmBH, Germany) following the manufacturer's instructions. The samples were diluted 200-fold using the provided EIA buffer to obtain biomarker levels within
the measurement range of the kit (1.56-100 ng/mL). Blood pressure was measured by
a physician during study recruitment.

Peripheral blood mononuclear cell (PBMC) isolation and serum collection. 4 5 Peripheral blood was obtained from study participants. Serum from tubes with coagulation activator was isolated by centrifugation and was either used immediately 6 or stored at -80C. PBMCs were isolated from heparinized blood by density gradient 7 centrifugation using Histopaque-1077 (Sigma-Aldrich, St. Louis, USA). After washing 8 with complete RPMI-1640 (10% fetal bovine serum and 1% penicillin-streptomycin in 9 RPMI-1640), PBMCs were resuspended in freezing media (90% fetal bovine serum 10 and 10% dimethyl sulfoxide) and cryopreserved. All laboratory analyses were done in 11 the Joint Laboratory at Pauls Stradins Clinical University Hospital (Riga, Latvia). 12

Immunophenotyping of peripheral blood B cells by flow cytometry. Using 13 antibodies against CD24, CD27, CD38 and IgD we were able to enumerate transitional 14 (CD24<sup>hi</sup>CD38<sup>hi</sup>), mature naive (CD24<sup>int</sup>CD38<sup>int</sup>), activated (CD24<sup>lo</sup>CD38<sup>lo</sup>), and total 15 memory (CD24<sup>hi</sup>CD38<sup>lo</sup>) B cells, including class-switched (IgD<sup>neg</sup>) and unswitched 16 (IgD<sup>pos</sup>) subsets, double negative (IgD<sup>neg</sup>CD27<sup>neg</sup>) B cells, pre-plasmablasts 17 (CD24<sup>lo</sup>CD38<sup>hi</sup>) and plasmablasts (CD27<sup>pos</sup>CD38<sup>hi</sup>). We further interrogated IgA, 18 CD21, T-bet, Ki-67 expression in B cell subsets. Briefly, for PBMC viability LIVE/DEAD 19 Fixable Near-IR Dead Cell Stain Kit was used (Invitrogen, MA, USA). Nonspecific 20 staining was prevented with Fc receptor blocking reagent (Miltenyi Biotec, Bergisch 21 Gladbach, Germany). The cells were incubated with antibodies (details see Suppl. 22 Table 1) for 40 minutes at 4C, afterwards unbound antibodies were removed by two 23 washes with flow cytometry staining buffer (2% fetal bovine serum and 2 mM EDTA in 24 phosphate-buffered solution (PBS)) and fixed with PBS containing 2% formaldehyde. 25 For intracellular and transcription factor staining, cells were fixed and permeabilized 26 using the Foxp3/Transcription Factor Staining Buffer Set (00-5523-00, eBioscience) 27 followed by incubation with antibodies diluted in permeabilization buffer for 50 minutes 28 at 4C. Samples were acquired on the Navios EX flow cytometer (Beckman Coulter, 29 Inc., Brea, CA, USA) and analysed with FlowJo software (BD Life Sciences). For the 30 detection of GdIgA1 B cells, we stained PBMCs with a fluorophore labelled (R10712 31 ReadyLabel<sup>™</sup>, Invitrogen, MA, USA) monoclonal antibody (Gd-IgA1 (KM55)-IBL 32 30117066, IBL Japan, Japan) at 37C for 40 minutes. To further enumerate Gd-IgA1 33

plasmablasts, cells were fixed again permeabilized using the Foxp3/Transcription
 Factor Staining Buffer Set and then stained intracellularly with the Gd-IgA1 monoclonal
 antibody.

Statistical analysis. All the statistical analyses were conducted using GraphPad Prism 9 (La Jolla, CA, USA). Data distribution was assessed by the Shapiro-Wilk test and normal Q-Q plots. For normally distributed and homogenous data, independent samples t-test was used; when data were not normally distributed, Mann-Whitney U test was used. Fisher's exact test was used to compare sex between groups. Spearman's rank correlation test was used to interrogate statistical significance in correlations. Results were considered statistically significant at p<0.05.</p>

#### 11 Results

To uncover B activation pathways and how peripheral B cell composition may be 12 impacted in patients with IgAN, we recruited 36 patients with IgAN and 19 healthy 13 14 controls (HCs). See Methods for full participant inclusion and exclusion criteria. The demographic, clinical and laboratory data of the cohort are summarised in Table 1. 15 16 Study participants were sex- and age-matched. Both groups had normal and comparable leukocyte and lymphocyte counts. As expected, IgAN patients had higher 17 serum creatinine levels and lower eGFR than HCs. IgAN patients represented all four 18 19 CKD stages (from 1 to 4) based on eGFR. The median proteinuria of patients with IgAN was 0,48 g/g (IQR 0,26-1,35), 11 patients had moderate proteinuria (1-3g) and 20 only one patient had nephrotic range proteinuria (>3g). According to the Oxford 21 classification of IgAN (19), a frequent histological finding was secondary 22 glomerulosclerosis (69,4%). Only in rare cases tubular atrophy or crescents in <25% 23 of glomeruli were seen. Of note, BMI is associated with worse presentation and long-24 term outcome of IgAN (20, 21), and B cell activation pathways are dysregulated in 25 obesity (22). In our cohort there were no significant differences in BMI between IgAN 26 patients and controls. 27

We first carried out B cell phenotyping based on CD24, CD27, CD38 and IgD surface expression. This allowed us to enumerate transitional (CD24<sup>hi</sup>CD38<sup>hi</sup>), mature naive (CD24<sup>int</sup>CD38<sup>int</sup>), activated (CD24<sup>lo</sup>CD38<sup>lo</sup>), and total memory (CD24<sup>hi</sup>CD38<sup>lo</sup>) B cells, including class-switched (IgD<sup>neg</sup>) and unswitched (IgD<sup>pos</sup>) subsets, double negative (IgD<sup>neg</sup>CD27<sup>neg</sup>) B cells, pre-plasmablasts (CD24<sup>lo</sup>CD38<sup>hi</sup>) and plasmablasts (CD27posCD38hi). The CD24/CD38 gating strategy confirmation is shown in Suppl.

7

Figure 1. We found that IgAN patients had a significant increase in mature naive B 1 cells with a reciprocal decrease in the frequency of total memory B cells (Figure 1a). 2 Frequencies of switched and unswitched memory B cells were comparable (Figure 3 1b). A novel population of IgD<sup>neg</sup>CD27<sup>neg</sup> B cells termed double negative (DN) or 4 atypical memory B cells has been recently described. These DN B cells are expanded 5 in autoimmune conditions, such as systemic lupus erythematosus (SLE), and 6 especially in those with nephritis (14, 15). These cells have been shown to be the 7 8 precursors of autoantibody-producing plasmablasts in SLE. Nevertheless, total double negative (DN) B cells and plasmablasts were comparable in patients with IgAN and 9 HCs (Figure 1c). 10

The cellular origin and pathway that gives rise to IgA-producing B cells in IgAN is 11 unknown, therefore, we next wanted to assay specifically IgA-expressing B cells and 12 antibody-secreting cells (ASCs). That is, we wanted to know if systemic perturbations 13 in the activation and differentiation of IgA-expressing B cells can be detected in patients 14 15 with IgAN. Among B cells, IgA-expressing classical memory (CD27<sup>pos</sup>) B cell frequency was comparable between IgAN patients and HCs (Figure 2a). However, we noted that 16 in addition to CD27-expressing B cells, there was a smaller population of IgA class-17 switched B cells that lacked CD27 expression, which was particularly pronounced in 18 IgAN patients. Indeed, there was a significant expansion of these IgA-expressing 19 CD27<sup>neg</sup> B cells in patients with IgAN (Figure 2a). We also detected a significantly 20 higher frequency of IgA class-switched ASCs in IgAN patients compared to controls 21 (Figure 2b). Supporting a lineage relationship between IgA-expressing plasmablasts 22 and IgA-expressing CD27<sup>neg</sup> B cells, we found a correlation between these two subsets 23 24 (Figure 2c).

We next wanted to address whether the IgA-expressing B cells were indeed 25 26 expressing GdIgA1. We found that IgA<sup>pos</sup>CD27<sup>neg</sup> B cells co-expressed GdIgA1 (Figure 2d). Reciprocally, in IgAN patients the majority of all GdIgA1<sup>+</sup> B cells were CD27<sup>neg</sup> 27 (Figure 2e,f). IgA<sup>pos</sup> plasmablasts also expressed high levels of GdIgA1 (Figure 2g). 28 Finally, implicating the IgA-expressing plasmablast as a potential functional contributor 29 to pathogenesis, we observed a correlation between IgApos plasmablasts and 30 31 circulating IgA levels (Figure 2h). Nevertheless, despite the correlation between IgA and GdIgA1, we did not find a relationship between IgApos plasmablasts and serum 32 GdlgA1 levels (Figure 2i). 33

CD27<sup>neg</sup> antigen-experienced B cells comprise two subsets, termed double negative 1 (DN) 1 and 2. DN1 cells are defined by their expression of CD21 and CXCR5, while 2 DN2 B cells lack CD21 and CXCR5 expression and instead express CD11c and are 3 transcriptionally regulated by T-bet (15). Based on their transcriptional signatures 4 these two subsets of B cells arise from different activation pathways (15). While DN2 5 B cells arise through extrafollicular B cell activation, DN1 B cells represent precursors 6 7 of classical memory B cells that have recently emerged from the germinal centre 8 reaction (and have not yet upregulated CD27). Of note, germinal centres are the microanatomical structures that allow the evolution (by somatic hypermutation of 9 antibody-encoding genes) and selection (affinity maturation) of B cells that enable the 10 production of high-affinity antibodies (23). The understanding of which pathway B cells 11 are activated through can elucidate factors that regulate the response (e.g. T cell help) 12 or properties of the compartment (e.g. longevity) (23). We found that the IgA<sup>neg</sup>CD27<sup>pos</sup> 13 B cells were phenotypically CD21<sup>hi</sup> and T-bet<sup>lo</sup> corresponding to DN1 phenotype 14 (Figure 3a), suggesting they may indeed be the precursors of IgA<sup>pos</sup>CD27<sup>pos</sup> classical 15 memory B cells. Of note, we used IgA<sup>pos</sup>CD27<sup>pos</sup> memory B cells as a control for high 16 expression of CD21 and lack of T-bet. To further interrogate this developmental 17 relationship, we reasoned that most of the classical memory compartment (CD27<sup>pos</sup>) 18 in patients with IgAN and HCs would be composed of foreign-antigen specific B cells 19 generated throughout the lifetime. The vast majority of this pool should be resting cells, 20 apart from those that report and participate in an on-going immune response. We then 21 carried out Ki-67 staining and found a significant positive correlation between 22 proliferating IgA<sup>pos</sup> DN1 and Ki-67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>pos</sup> memory B cells (Figure 3b). 23 Therefore, the shared phenotypic and proliferation characteristics of these subsets 24 suggest a developmental relationship and support increased generation of IgA-25 expressing ASCs through the germinal centre pathway. 26

Finally, we wanted to explore the mucosal-kidney axis in relation to B cell activation in 27 IgAN and ask if previously reported perturbations at mucosal surfaces were linked to 28 this DN1 B cell differentiation pathway. LPS is known to not only influence B cell class-29 switching to IgA (24, 25) but is also used as a surrogate marker of dysbiosis and gut 30 permeability (26-29). We found that LPS was significantly elevated in the serum of 31 32 IgAN patients compared to HCs (Figure 4a), confirming previously published data (30). We further found that IgA-expressing CD27<sup>neg</sup> B cells correlated with serum LPS levels 33 (Figure 4b; the relationships between LPS and the other B cell subsets examined in 34

9

this study are presented in Suppl. Table 2). This suggests LPS may either directly drive 1 their expansion/class-switching or that the observed correlation is because both 2 increased LPS and IgA<sup>pos</sup>CD27<sup>neg</sup> B cells are a consequence of mucosal 3 dysbiosis/reduced barrier function, which contributes to IqA-expressing plasmablast 4 differentiation. Finally, we wanted to ask how the expansion of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells 5 related to clinical features of IgAN. We found that specifically in patients with reduced 6 kidney function (eGFR <90mL/min) there was an inverse correlation between eGFR 7 and the frequency of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells (Figure 4c). 8

9

#### 10 Discussion

The multi-hit model is the blueprint for explaining IgAN aetiopathogenesis (7-10). 11 Advances have been made particularly in uncovering the mechanisms operating within 12 the kidney that contribute to organ damage (hit 4, see Figure 5). These include the 13 14 dissection of how immune complexes containing IgA bind to mesangial cells, triggering proliferation and increased synthesis of extracellular matrix components as well as the 15 role of the CD89, the IgA Fc receptor, in regulating tissue damage (31, 32). However, 16 17 these mechanistic insights are unlikely to provide the key to therapeutic advances as they operate once B cell tolerance is already broken. 18

We report here that global alterations in the B cell compartment are present in patients 19 with IgAN, specifically the expansion of naive B cells and a reduction in total memory 20 B cells. This observation is of significance as IgAN is considered an organ-specific 21 autoimmune disease, yet these data support that systemic immunity is dysregulated 22 beyond that which has been previously described at mucosal sites (33-35). Increase 23 in naive B cells and reduction in total memory B cells is characteristic of systemic 24 autoimmune diseases such as systemic lupus erythematosus (SLE) and conditions 25 associated with chronic low-grade inflammation, including obesity (15, 22). However, 26 we did not observe an expansion of total DN B cells associated with most severe 27 systemic autoimmune and inflammatory phenotypes. It will be important to address 28 whether the systemic changes in the overall B cell landscape we report here are causal 29 30 to IgAN or a consequence of autoimmunity-associated inflammation/bystander effects.

As the source of pathogenic Gd-IgA1 antibodies, B cells are a promising target in IgAN, but B cell activation and differentiation pathways that lead to pathogenic IgA production

remain uncharacterised. Understanding how B cells are affected and become activated 1 is thus important for the complete understanding of IgAN pathogenesis, prognosis, and 2 treatment. Here we provide mechanistic insight into the early steps of IgAN 3 aetiopathogenesis by uncovering that IgA-expressing B cells that lack the classical 4 memory marker CD27 but express CD21 are expanded in patients with IgAN and 5 appear to be the cellular precursors of IgA-producing plasmablasts. We show that such 6 7 ASC precursors are apparently recent emigrants from on-going germinal centres, 8 which suggests the continuous output of the pathogenic precursors, rather than dominant contribution by memory B cells and plasmablasts differentiated at an earlier 9 timepoint. DN1 B cells have not been previously associated with disease states (unlike 10 the extensively characterised DN2 subset) therefore, this work may help uncover more 11 about this B cell population. This observation of increased recent germinal centre 12 emigrant DN1 B cells also fits with the report of increased frequency of Tfh cells in 13 IgAN patients (36). 14

15 That we found a correlation between the CD27<sup>neg</sup> precursors of IgA-expressing plasmablasts and serum LPS levels, implicates mucosal immunity in the differentiation 16 of these cells. LPS could directly contribute to class-switching in activated B cells as 17 previously observed (24, 25). In support of direct activation, tonsillar B cells from IgAN 18 patients have been shown to produce increased IgA in response to LPS stimulation 19 (37). Others have shown that upon in vitro culture with LPS, B cells downregulate the 20 expression of  $\beta$ 3-galactosyltransferase-specific molecular chaperone (Cosmc) (38). 21 Therefore, LPS may act at multiple stages of B cell activation to not only induce class-22 switching and IgA production, but to also regulate IgA glycosylation. Another possible 23 24 explanation for the correlation between IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and LPS is that both are increased as a consequence of intestinal inflammatory processes that may result in 25 enhanced generation of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and increased intestinal permeability. 26 Supporting the mucosa as a site of origin for these IgA-expressing B cells, IgAN 27 patients have an increased frequency of IgApos B cells that express the mucosal 28 homing marker CCR9 (18). It is possible that tonsillectomy, a procedure that has 29 demonstrated to be of some benefit in IgAN (39, 40), may eliminate the niche of either 30 generation or homing of these B cells as has been speculated by others (41). It may 31 32 also provide clues as to why B cell depletion has shown variable success in IgAN despite the central role of B cells in the disease pathogenesis (42)- the mucosal niches 33 may harbour the majority of precursors that are not efficiently depleted by the B cell 34

targeting therapy. Albeit the literature is not consistent, studies have suggested that 1 rituximab may be less effective in depleting B cells within lymphoid tissues (43). Recent 2 findings of disease-modifying effects of enteral budesonide in IgAN further implicate 3 mucosal sites in driving immunopathogenesis (44). Whether budesonide affects B cell 4 phenotypes remains to be determined, but it is tempting to speculate that it indirectly 5 targets IgA<sup>pos</sup> ASC precursors at mucosal sites. Additionally in other autoimmune 6 diseases both memory B cells and B cells de novo engaging in immune responses -7 8 such as germinal centre B cells which are the proposed progenitors of DN1 B cells have been shown to be resistant to rituximab treatment (45, 46). 9

10 In IgAN endocapillary proliferation, tubular atrophy/interstitial fibrosis are independent predictors of rate of loss of renal function (47). In our cohort of IgAN patients, the 11 prevalence of these findings was relatively low. It is important to note that kidney biopsy 12 may have been conducted several years before the patient's visit. The distribution of 13 men, as well as the age and BMI, was found to be similar to that reported in other 14 15 studies focusing on IgAN. Clinically, patients exhibited lower protein excretion, yet their eGFR was worse when compared to the results of other studies evaluating B cells in 16 IgAN (16, 18). Of note, a limitation of the study is that our cohort consisted entirely of 17 white Eastern Europeans and thus the B cell activation pathway we have uncovered 18 remains to investigated in non-European cohorts. 19

20 Now that we have identified the aberrant B cell differentiation pathways in IgAN. important further questions can be addressed. Due to their expression of GdIgA1, it is 21 tempting to speculate that IgA<sup>pos</sup>CD27<sup>neg</sup> cells participate in disease precipitation, 22 albeit this remains to be experimentally demonstrated. That is, the enhanced 23 generation of IgA<sup>pos</sup>CD27<sup>neg</sup> precursors could drive disease or these cells may be 24 generated as part of ongoing inflammation and not causal in IgAN development. Since 25 this study aimed to capture the whole range of IgAN clinical features, our cohort 26 comprised only 6 patients with eGFR>90mL/min. We speculate that if the B cell 27 dysregulation we characterise here underlies disease, patients would present with an 28 increased activation of this pathway prior to detectable decline in renal function. With 29 regards to the antigen specificity and clonality of IgA-expressing B cells: what are the 30 B cells recognising (e.g. food, microbial antigens) and how diverse is the IgA response 31 within an individual and between individuals? With regards to the site of induction and 32 long-term residence – where are the IgA-expressing plasmablast precursors induced 33

1 and maintained (e.g. mucosa, bone marrow) and is this shared across IgAN patients?

2 How are pathogenic IgA<sup>pos</sup>CD27<sup>neg</sup> B cells different from foreign-antigen reactive

3 IgA<sup>pos</sup>CD27<sup>pos</sup> B cells- can targets be identified to specifically deplete or inhibit the

4 differentiation of pathogenic B cells?

In summary, we propose that dysregulation of mucosal immunity may drive the
 increased naïve B cell activation in germinal centres, giving rise to
 IgA<sup>pos</sup>CD27<sup>neg</sup>CD21<sup>pos</sup> B cells and subsequently IgA-producing plasmablasts; this
 pathway can be further explored for biomarkers and therapeutic targets in IgAN.

# 9 Data availability statement:

10 The data that support the findings of this study are available in the article and in its

11 online supplementary material.

# 12 Acknowledgements:

13 We thank Dr Elizabeth C. Rosser for critically reviewing the manuscript and all the 14 study participants, who made this research possible.

# 15 Funding:

16 This work was funded by the Latvian Council of Science, project Nr. lzp-2019/1-0139.

# 17 Authors' contributions:

AP, KR, VK, JK, AL, KO designed the study; AP, KR, VK, HC, AP were responsible for
patient and control group selection and enrolment; AP, KR, VK, MS, JS, AJS, AV
collected patient medical histories, obtained patient samples; AP, BS, KR, VK, RK,
MS, JS, AJS, AV, KV, DP, JK, HC, AL, AP, KO conducted experiments and analysed
data; KO and RK interpreted results, wrote and revised the manuscript and all authors
contributed to the final manuscript.

# 24 Conflict of interest statement:

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

- 28
- 29
- 30
- 31
- 32

#### 1 References:

McGrogan A, Franssen CF, de Vries CS. The incidence of primary
 glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial
 Transplant. 2011;26(2):414-30.

Lafayette RA, Kelepouris E. Immunoglobulin A Nephropathy: Advances in
 Understanding of Pathogenesis and Treatment. Am J Nephrol. 2018;47 Suppl 1:43 52.

Berthoux FC, Mohey H, Afiani A. Natural history of primary IgA nephropathy.
 Semin Nephrol. 2008;28(1):4-9.

Gleeson PJ, O'Shaughnessy MM, Barratt J. IgA nephropathy in adults Treatment Standard. Nephrol Dial Transplant. 2023.

Ponticelli C, Locatelli F. Corticosteroids in IgA Nephropathy. Am J Kidney Dis.
 2018;71(2):160-2.

Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin
 Immunopathol. 2021;43(5):717-28.

Suzuki H, Kiryluk K, Novak J, Moldoveanu Z, Herr AB, Renfrow MB, et al. The
 pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22(10):1795-803.

Magistroni R, D'Agati VD, Appel GB, Kiryluk K. New developments in the
 genetics, pathogenesis, and therapy of IgA nephropathy. Kidney Int. 2015;88(5):974 89.

Gentile M, Sanchez-Russo L, Riella LV, Verlato A, Manrique J, Granata S, et al.
 Immune abnormalities in IgA nephropathy. Clin Kidney J. 2023;16(7):1059-70.

23 10. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402-14.

Novak J, Julian BA, Tomana M, Mestecky J. IgA glycosylation and IgA immune
 complexes in the pathogenesis of IgA nephropathy. Semin Nephrol. 2008;28(1):78-87.

Moldoveanu Z, Wyatt RJ, Lee JY, Tomana M, Julian BA, Mestecky J, et al.
Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels.
Kidney Int. 2007;71(11):1148-54.

14

13. Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune mediated kidney disease. Nat Rev Nephrol. 2019;15(1):11-26.

14. Tipton CM, Fucile CF, Darce J, Chida A, Ichikawa T, Gregoretti I, et al. Diversity,
cellular origin and autoreactivity of antibody-secreting cell population expansions in
acute systemic lupus erythematosus. Nat Immunol. 2015;16(7):755-65.

Jenks SA, Cashman KS, Zumaquero E, Marigorta UM, Patel AV, Wang X, et al.
Distinct Effector B Cells Induced by Unregulated Toll-like Receptor 7 Contribute to
Pathogenic Responses in Systemic Lupus Erythematosus. Immunity. 2018;49(4):72539 e6.

16. Wang YY, Zhang L, Zhao PW, Ma L, Li C, Zou HB, et al. Functional implications
of regulatory B cells in human IgA nephropathy. Scand J Immunol. 2014;79(1):51-60.

17. Sendic S, Mansouri L, Lundberg S, Nopp A, Jacobson SH, Lundahl J. B cell and
monocyte phenotyping: A quick asset to investigate the immune status in patients with
IgA nephropathy. PLoS One. 2021;16(3):e0248056.

18. Sallustio F, Curci C, Chaoul N, Fonto G, Lauriero G, Picerno A, et al. High levels
of gut-homing immunoglobulin A+ B lymphocytes support the pathogenic role of
intestinal mucosal hyperresponsiveness in immunoglobulin A nephropathy patients.
Nephrol Dial Transplant. 2021;36(3):452-64.

Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford
 Classification of IgA nephropathy 2016: an update from the IgA Nephropathy
 Classification Working Group. Kidney Int. 2017;91(5):1014-21.

20. Kataoka H, Ohara M, Shibui K, Sato M, Suzuki T, Amemiya N, et al. Overweight
and obesity accelerate the progression of IgA nephropathy: prognostic utility of a
combination of BMI and histopathological parameters. Clin Exp Nephrol.
2012;16(5):706-12.

26 21. Hong YA, Min JW, Ha MA, Koh ES, Kim HD, Ban TH, et al. The Impact of
27 Obesity on the Severity of Clinicopathologic Parameters in Patients with IgA
28 Nephropathy. J Clin Med. 2020;9(9).

29 22. Slisere B, Arisova M, Aizbalte O, Salmina MM, Zolovs M, Levensteins M, et al.
30 Distinct B cell profiles characterise healthy weight and obesity pre- and post-bariatric
31 surgery. Int J Obes (Lond). 2023;47(10):970-8.

23. Elsner RA, Shlomchik MJ. Germinal Center and Extrafollicular B Cell
 Responses in Vaccination, Immunity, and Autoimmunity. Immunity. 2020;53(6):1136 50.

4 24. Stavnezer J, Guikema JE, Schrader CE. Mechanism and regulation of class
5 switch recombination. Annu Rev Immunol. 2008;26:261-92.

6 25. Cerutti A. The regulation of IgA class switching. Nat Rev Immunol.7 2008;8(6):421-34.

Scaldaferri F, Lopetuso LR, Petito V, Cufino V, Bilotta M, Arena V, et al. Gelatin
tannate ameliorates acute colitis in mice by reinforcing mucus layer and modulating
gut microbiota composition: Emerging role for 'gut barrier protectors' in IBD? United
European Gastroenterol J. 2014;2(2):113-22.

27. Zhao H, Zhang H, Wu H, Li H, Liu L, Guo J, et al. Protective role of 1,25(OH)2
vitamin D3 in the mucosal injury and epithelial barrier disruption in DSS-induced acute
colitis in mice. BMC Gastroenterol. 2012;12:57.

Yu LC, Flynn AN, Turner JR, Buret AG. SGLT-1-mediated glucose uptake
protects intestinal epithelial cells against LPS-induced apoptosis and barrier defects: a
novel cellular rescue mechanism? FASEB J. 2005;19(13):1822-35.

Nighot M, Al-Sadi R, Guo S, Rawat M, Nighot P, Watterson MD, et al.
Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is
Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88
(MyD88) Activation of Myosin Light Chain Kinase Expression. Am J Pathol.
2017;187(12):2698-710.

30. Tang Y, Zhu Y, He H, Peng Y, Hu P, Wu J, et al. Gut Dysbiosis and Intestinal
Barrier Dysfunction Promotes IgA Nephropathy by Increasing the Production of GdIgA1. Front Med (Lausanne). 2022;9:944027.

Launay P, Grossetete B, Arcos-Fajardo M, Gaudin E, Torres SP, Beaudoin L,
et al. Fcalpha receptor (CD89) mediates the development of immunoglobulin A (IgA)
nephropathy (Berger's disease). Evidence for pathogenic soluble receptor-Iga
complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191(11):19992009.

32. Van der Steen LP, Bakema JE, Sesarman A, Florea F, Tuk CW, Kirtschig G, et
 al. Blocking Fcalpha receptor I on granulocytes prevents tissue damage induced by
 IgA autoantibodies. J Immunol. 2012;189(4):1594-601.

33. Bene MC, Hurault De Ligny B, Kessler M, Faure GC. Confirmation of tonsillar
anomalies in IgA nephropathy: a multicenter study. Nephron. 1991;58(4):425-8.

G 34. Sugiyama N, Shimizu J, Nakamura M, Kiriu T, Matsuoka K, Masuda Y.
Clinicopathological study of the effectiveness of tonsillectomy in IgA nephropathy
accompanied by chronic tonsillitis. Acta Otolaryngol Suppl. 1993;508:43-8.

9 35. Harper SJ, Allen AC, Bene MC, Pringle JH, Faure G, Lauder I, et al. Increased
10 dimeric IgA-producing B cells in tonsils in IgA nephropathy determined by in situ
11 hybridization for J chain mRNA. Clin Exp Immunol. 1995;101(3):442-8.

36. Zhang L, Wang Y, Shi X, Zou H, Jiang Y. A higher frequency of
CD4(+)CXCR5(+) T follicular helper cells in patients with newly diagnosed IgA
nephropathy. Immunol Lett. 2014;158(1-2):101-8.

15 37. Liu H, Peng Y, Liu F, Xiao W, Zhang Y, Li W. Expression of IgA class switching
16 gene in tonsillar mononuclear cells in patients with IgA nephropathy. Inflamm Res.
17 2011;60(9):869-78

38. Qin W, Zhong X, Fan JM, Zhang YJ, Liu XR, Ma XY. External suppression
causes the low expression of the Cosmc gene in IgA nephropathy. Nephrol Dial
Transplant. 2008;23(5):1608-14.

39. Hirano K, Matsuzaki K, Yasuda T, Nishikawa M, Yasuda Y, Koike K, et al.
Association Between Tonsillectomy and Outcomes in Patients With Immunoglobulin A
Nephropathy. JAMA Netw Open. 2019;2(5):e194772.

40. Feriozzi S, Polci R. The role of tonsillectomy in IgA nephropathy. J Nephrol.
2016;29(1):13-9.

41. Wu G, Peng YM, Liu FY, Xu D, Liu C. The role of memory B cell in tonsil and
peripheral blood in the clinical progression of IgA nephropathy. Hum Immunol.
2013;74(6):708-12.

42. Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. A
 Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and
 Renal Dysfunction. J Am Soc Nephrol. 2017;28(4):1306-13.

4 43. Otten HG, Hans, Kyra, ten M, Leo, Hilbrands LB. A Single Dose of Rituximab
5 Does Not Deplete B Cells in Secondary Lymphoid Organs but Alters Phenotype and
6 Function. American Journal of Transplantation. 2013 Jun 1;13(6):1503–11.

44. Lafayette R, Kristensen J, Stone A, Floege J, Tesar V, Trimarchi H, et al.
Efficacy and safety of a targeted-release formulation of budesonide in patients with
primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lancet. 2023;402(10405):859-70.

45. Etienne Crickx, Pascal Chappert, Sokal A, Weller S, Imane Azzaoui,
Vandenberghe A, et al. Rituximab-resistant splenic memory B cells and newly engaged
naive B cells fuel relapses in patients with immune thrombocytopenia. Science
Translational Medicine. 2021 Apr 14;13(589).

46. Jiang R, Fichtner ML, Hoehn KB, Pham MC, Stathopoulos P, Nowak RJ, et al.
Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia
gravis relapses. JCI Insight. 2020 Jul 23;5(14).

47. Chakera A, MacEwen C, Bellur SS, Chompuk LO, Lunn D, Roberts ISD.
Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no
immunosuppression. J Nephrol. 2016;29(3):367-75.

21

#### 22 Tables + table legends:

Table 1. Demographic, clinical and laboratory characteristics of the study cohort
 (median, minimum-maximum, IQR).

25

# 26 Figures + figure legends:

Figure 1. IgAN-associated changes in the peripheral B cell landscape. Representative flow cytometry plots and summary bar charts demonstrating (a) the frequencies of transitional (CD24<sup>hi</sup>CD38<sup>hi</sup>), mature (CD24<sup>int</sup>CD38<sup>int</sup>), memory (CD24<sup>hi</sup>CD38<sup>lo</sup>), and activated B cells (CD24<sup>lo</sup>CD38<sup>lo</sup>) and pre-plasmablasts (CD24<sup>lo</sup>CD38<sup>hi</sup>), (b) the

distribution of memory B cells into IgD<sup>pos</sup> unswitched and IgD<sup>neg</sup> class-switched 1 subsets, (c) the frequencies of total double negative (DN; IgD<sup>neg</sup>CD27<sup>neg</sup>) B cells and 2 plasmablasts (CD27<sup>pos</sup>CD38<sup>hi</sup>) in IgAN patients and healthy controls. Data are 3 mean±SD and each circle/square represents a study participant. For normally 4 distributed CD24<sup>int</sup>CD38<sup>int</sup>, CD24<sup>hi</sup>CD38<sup>lo</sup>, IgD<sup>pos</sup> memory and IgD<sup>neg</sup> memory B cell 5 populations independent samples t test was used to compare IgAN patients and 6 For non-normally distributed CD24<sup>hi</sup>CD38<sup>hi</sup>, CD24<sup>lo</sup>CD38<sup>lo</sup>, 7 healthy controls. CD24<sup>lo</sup>CD38<sup>hi</sup>, IgD<sup>neg</sup>CD27<sup>neg</sup> and CD27<sup>pos</sup>CD38<sup>hi</sup> B cell subsets Mann-Whitney U test 8 was used for the comparison of IgAN patients and HCs. 9

10

Figure 2. Enhanced differentiation of IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and IgA<sup>pos</sup> plasmablasts in 11 IgAN. Representative flow cytometry plots and summary bar charts demonstrating the 12 frequencies of (a) IgA<sup>pos</sup>CD27<sup>pos</sup> and IgA<sup>pos</sup>CD27<sup>neg</sup> B cells and (b) IgA<sup>pos</sup> 13 plasmablasts, (c) linear regression analysis of IgApos CD27<sup>neg</sup> B cells versus IgApos 14 plasmablasts, (d) representative flow cytometry histograms and summary bar charts 15 demonstrating the median fluorescence intensity of GdIgA1 in IgApos and IgAneg 16 CD19<sup>pos</sup>CD27<sup>neg</sup> B cells, (e, f) representative flow cytometry plots and summary bar 17 charts demonstrating the frequencies of (e) GdlgA1<sup>pos</sup> B cells and (f) the distribution of 18 GdlgA1<sup>pos</sup> B cells into CD27<sup>neg</sup> and CD27<sup>pos</sup> subsets, (g) representative flow cytometry 19 histograms and summary bar charts demonstrating the median fluorescence intensity 20 of GdlgA1 in IgA<sup>pos</sup> and IgA<sup>neg</sup> plasmablasts, (h, i) linear regression analysis of (h) 21 serum IgA levels versus IgA<sup>pos</sup> plasmablasts and (i) serum GdIgA1 versus serum IgA 22 levels in IgAN patients and healthy controls. Data are mean±SD and each circle/square 23 represents a study participant. For non-normally distributed subsets Mann-Whitney U 24 test was used for the comparison of IgAN patients and HCs. Spearman's rank 25 correlation tests were used to interrogate statistical significance in the correlation 26 between IgAposCD27<sup>neg</sup> B cells and IgApos plasmablasts, serum IgA levels and IgApos 27 plasmablasts and serum GdIqA1 and serum IqA levels in IqAN patients and HCs. 28

29

Figure 3. IgA<sup>pos</sup>CD27<sup>neg</sup> B cells are phenotypically CD21<sup>+</sup>T-bet<sup>-</sup>. Representative flow cytometry histograms and summary bar charts demonstrating the median fluorescence intensity of CD21 (a) and T-bet (b) in IgA<sup>pos</sup>CD27<sup>neg</sup> and IgA<sup>pos</sup>CD27<sup>pos</sup> B cells, (c) representative flow cytometry plots and linear regression analysis of Ki-

67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>pos</sup> B cells versus Ki-67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>neg</sup> B cells in HCs and IgAN patients. Data are mean±SD and each circle/square represents a study participant. For non-normally distributed CD21 and T-bet MFI Mann-Whitney U test was used for the comparison of IgAN patients and healthy controls. Spearman's rank correlation test was used to interrogate statistical significance in correlations between Ki-67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>pos</sup> B cells and Ki-67<sup>pos</sup>IgA<sup>pos</sup>CD27<sup>neg</sup> B cells in IgAN patients and HCs.

7

Figure 4. Serum LPS levels correlate with IgA<sup>pos</sup>CD27<sup>neg</sup> B cell frequency. (a) 8 Summary bar chart showing serum LPS levels and (b) linear regression analysis of 9 serum LPS levels versus IgA<sup>pos</sup>CD27<sup>neg</sup> B cells in IgAN patients and HCs. (c) Linear 10 regression analysis of eGFR versus IgA<sup>pos</sup>CD27<sup>neg</sup> B cells in IgAN patients. Data are 11 mean±SD and each circle/square represents a study participant. For non-normally 12 distributed serum LPS levels Mann-Whitney U test was used for the comparison of 13 IgAN patients and healthy controls. Spearman's rank correlation test was used to 14 interrogate statistical significance in the correlation between serum LPS levels and 15 IgA<sup>pos</sup>CD27<sup>neg</sup> B cells in IgAN patients and HCs. 16

17

Figure 5. Revised multi-hit model with integration of B cell activation pathways. Hit 1 18 of the multi-hit pathogenesis is the production of pathogenic galactose-deficient IgA1 19 (Gd-IgA1). This is followed by production of anti-IgA antibodies (Hit 2) and formation 20 of immune complexes (Hit 3), which are finally deposited in the kidney glomeruli and 21 cause tissue damage and renal decline. Here we have uncovered the B cell pathway 22 that leads to Gd-IgA1 production (hit 1) in IgAN pathogenesis, and term it 'hit 0'. 23 Specifically, naive B cells are de novo activated within germinal centers and give rise 24 to IgA<sup>pos</sup>CD27<sup>neg</sup> DN1 B cells and subsequently IgA-expressing plasmablasts which 25 secrete pathogenic IgA. 26

Baseline characteristics	HC, n = 19	IgAN patients, n = 36	p-value
Age, yr	49 (23-66, IQR 38-53)	44,5 (22-65, IQR 37-50)	0,906
Male	13 (68,4%)	23 (63,9%)	0,775
BMI, kg/m²	26,8 (17,82-40,63, IQR 23,4-31,1)	25,5 (17,6-44,1, IQR 23,4-29,4)	0,816
Systolic BP, mmHg	122 (98-145, IQR 120-129)	139 (120-174, IQR 130-152)	<0,001
Diastolic BP, mmHg	80 (60-98, IQR 74-85)	85 (70-110, IQR 80-95)	0,024
Serum creatinine, µmol/l	83 (55-102, IQR 74-87)	126,5 (49-402, IQR 95,5-214)	<0,001
eGFR, ml/min per 1,73m <sup>2</sup>	100 (70-128, IQR 96-107)	56 (15-131, IQR 25,5-85,5)	<0,001
CKD stage 1		6 (16,7%)	
CKD stage 2		12 (33,3%)	
CKD stage 3		7 (19,4%)	
CKD stage 4		11 (30,6%)	
Proteinuria, g/g		0,48 (0,07-6,18, IQR 0,26-1,35)	
Hematuria, RBC/µl		21,17 (0-1421, IQR 10-65)	
Serum albumin, g/l		46 (29-51, IQR 42,5-48)	
Serum total cholesterol, mmol/l		5,46 (3,79-8,11, IQR 4,94-5,9)	
Absolute leukocyte count, 10 <sup>9</sup> /l	5,3 (4,1-8,4, IQR 4,4-6,5)	7,15 (4,2-12,8, IQR 5,8-7,5)	0,07
Absolute lymphocyte count, 10 <sup>9</sup> /l	1,9 (1,4-3,0, IQR 1,8-2,4)	1,8 (0,9-3,1, IQR 1,5-2,2)	0,291
Oxford classification			
M1		29 (80,6%)	
E1		1 (2,8%)	
S1		25 (69,4%)	
T1		2 (5,6%)	
T2		2 (5,6%)	
C1		2 (5,6%)	

**Table 1.** Demographic, clinical and laboratory characteristics of the cohort.













